drugset
drugset / Trial / NCT02182271

Single Rising Dose Study of BI 201335 ZW in Healthy Male Subjects

NCT02182271 ↗

Phase 1 Terminated 8 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

The objective of the current study is to investigate safety, tolerability, and pharmacokinetics of BI 201335 ZW following administration of single rising doses from 5 mg to 1500 mg. In addition Two stage intra-subject bioavailability comparison of 600 mg BI 201335 ZW as a liquid formulation given with and without food.

Timeline

Start
2004-10
Primary completion
2004-10
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 201335 ZW Unknown 5 mg Oral
Subject BI 201335 ZW Unknown 20 mg Oral
Subject BI 201335 ZW Unknown 60 mg Oral
Subject BI 201335 ZW Unknown 150 mg Oral
Subject BI 201335 ZW Unknown 300 mg Oral
Subject BI 201335 ZW Unknown 600 mg Oral
Subject BI 201335 ZW Unknown 1000 mg Oral
Subject BI 201335 ZW Unknown 1500 mg Oral

Indications

No indication recorded.